## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Olaf WILHELM et al Docket No. 2923-576

Serial Number: New Application Customer No.: 06449

Filed: October 24, 2003

For: NOVEL UROKINASE INHIBITORS

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith Form PTO-1449 listing publications that the Office may wish to consider in examination of the subject application.

Pursuant to 1.98(d), copies of the references are not included because they were previously submitted to the Office in prior application Serial No. 10/202,850, filed July 26, 2002 and 09/743,800 filed April 3, 2001.

Respectfully submitted,

Ву

Monica Chin Kitts

Attorney for Applicants

Registration No. 36,105

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040

						Complete if Known						
INFORMATION DISCLOSURE					Applic	Application Number New Application						
					Filing	Date	e	October 24, 2003				
STATEMENT BY APPLICANT						Vam	ed Inventor	Olaf WILHELM et al				
					Group	Art	Unit					
						iner	Name					
Sheet	1		of	2	Attorn	ey D	ocket Number	2923-576				
					U.S. PA	TEN	T DOCUMENTS					
•	Cite No.1		ent Docume	ent					Data of Dublination			
Examiner Initials*					nd Code <sup>2</sup>				Date of Publication of Cited Document MM-DD-YYYY		t	
				FO	REIGN I	PAT	ENT DOCUMEN	тѕ				
	Cite No.1		Patent Docu	ument	nent				Data of Dublication of			
Examiner Initials*		Office <sup>3</sup> Number <sup>4</sup> Code			Kind <sup>5</sup> (if knov		Name of Patentee of Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY		T <sup>6</sup>	
		WO 96/0		189					2/2	22/96		
		wo	92/087	709					3/2	29/92		
		wo	94/181	185					8/1	8/94		
		EP	0 183	271					6/4	1/86		
		DE	30 35	086					4/9	)/81		
		WO 95/17885							7/6	5/94		
		wo	00/171	158					3/3	30/00		
Examiner Signature								Date Considered				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Complete if Known						
					Application Number	New Application					
					Filing Date	October 24, 2003					
SIAIE	IVI EIN I	DT /	APPLIU	AINI	First Named Inventor	Olaf WILHELM et al					
					Group Art Unit						
					Examiner Name						
Sheet	Sheet 2 of 2				Attorney Docket Number	2923-576					
				NON PA	TENT LITERATURE DOCUM	MENTS					
Examiner Initials*	Cite No.1										
		com	Suerzebecher et al. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and Urokinase, J. Med. Chem. 41:5445-5456, 1998.								
		PEN	PENTAPHARM Product Catalog 1998 (copy affached)								
		!									
Examiner Signature						Date Considered					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.